2-amino-5,5-dimethyl-4,7-dihydrothieno[2,3-c]pyran-3-carboxamide | 86245-43-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡喃类
• 英文名称: 2-amino-5,5-dimethyl-4,7-dihydrothieno[2,3-c]pyran-3-carboxamide
• 英文别名: 2-amino-5,5-dimethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxamide
• CAS: 86245-43-4
• 化学式: C₁₀H₁₄N₂O₂S
• mdl: MFCD10038430
• 分子量: 226.299
• InChiKey: XMKZPJYWSUMTFN-UHFFFAOYSA-N

物化性质

• 熔点：
  160-161 °C(Solv: hexane (110-54-3))
• 沸点：
  352.1±42.0 °C(Predicted)
• 密度：
  1.284±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-amino-5,5-dimethyl-4,7-dihydrothieno[2,3-c]pyran-3-carboxamide 在 吡啶 、 potassium carbonate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 17.0h， 生成 2-(2-hydroxybenzamido)-5,5-dimethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide
  参考文献：
  名称：

  Discovery of N-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent

  摘要：

  Cystic fibrosis (CF) is caused by mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR). With the discovery of Ivacaftor and Orkambi, it has been shown that CFTR function can be partially restored by administering one or more small molecules. These molecules aim at either enhancing the amount of CFTR on the cell surface (correctors) or at improving the gating function of the CFTR channel (potentiators). Here we describe the discovery of a novel potentiator GLPG1837, which shows enhanced efficacy on CFTR mutants harboring class III mutations compared to Ivacaftor, the first marketed potentiator. The optimization of potency, efficacy, and pharmacokinetic profile will be described.

  DOI：

  10.1021/acs.jmedchem.7b01288
• 作为产物：
  描述：

  (2E)-2-cyano-2-(2,2-dimethyloxan-4-ylidene)acetamide 以76%的产率得到
  参考文献：
  名称：

  NORAVYAN, A. S.;OGANISYAN, A. SH.;BASENTSYAN, K. E.;VARTANYAN, S. A., ARM. XIM. ZH., 1983, 36, N 2, 108-115

  摘要：

  DOI：

文献信息

• Heterobicyclic Compounds as Pharmaceutically Active Agents
  申请人：Koul Anil

  公开号：US20070275962A1

  公开（公告）日：2007-11-29

  Described are heterobicyclic compounds such as 4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]thiopyran 3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid amides, or benzo[b]thiophene-3-carboxylic acid amides and pharmaceutically acceptable salts thereof, the use of these derivatives for the prophylaxis and/or treatment of various diseases such as infectious diseases, including mycobacteriainduced infections and opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, as well as compositions containing at least one heterobicyclic compound and/or pharmaceutically acceptable salts thereof. Furthermore, reaction procedures for the synthesis of the heterobicyclic compound are disclosed.

  本文介绍了异杂双环化合物，例如4,5,6,7-四氢苯并[b]噻吩-3-羧酸酰胺，4,7-二氢-5H-噻吩[2,3-c]硫杂吡喃-3-羧酸酰胺，4,7-二氢-5H-噻吩[2,3-c]吡喃-3-羧酸酰胺，或苯并[b]噻吩-3-羧酸酰胺及其药学上可接受的盐。这些衍生物的用途包括预防和/或治疗各种疾病，如传染性疾病，包括分支杆菌感染和机会性疾病，朊病，免疫性疾病，自身免疫性疾病，双相和临床障碍，心血管疾病，细胞增殖性疾病，糖尿病，炎症，移植排斥，勃起功能障碍，神经退行性疾病和中风，以及含有至少一种异杂双环化合物和/或药学上可接受的盐的组合物。此外，还公开了合成异杂双环化合物的反应程序。
• MKRTCHYAN, A. P.;KAZARYAN, S. G.;NORAVYAN, A. S.;VARTANYAN, S. A.;DZHAGAT+, ARM. XIM. ZH., 40,(1987) N 9, 581-587
  作者：MKRTCHYAN, A. P.、KAZARYAN, S. G.、NORAVYAN, A. S.、VARTANYAN, S. A.、DZHAGAT+

  DOI：——

  日期：——
• HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS
  申请人：GPC Biotech AG

  公开号：EP1670804A2

  公开（公告）日：2006-06-21
• [EN] HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS<br/>[FR] COMPOSES HETEROBICYCLIQUES EN TANT QU'AGENTS ACTIFS AU NIVEAU PHARMACEUTIQUE
  申请人：AXXIMA PHARMACEUTICALS AG

  公开号：WO2005023818A2

  公开（公告）日：2005-03-17

  Described are heterobicyclic compounds such as 4,5,6,7-tetrahydro­benzo[b]thiophene-3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]thiopyran­ 3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid amides, or benzo[b]thiophene-3-carboxylic acid amides and pharmaceutically acceptable salts thereof, the use of these derivatives for the prophylaxis and/or treatment of various diseases such as infectious diseases, including mycobacteria­induced infections and opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, as well as compositions containing at least one heterobicyclic compound and/or pharmaceutically acceptable salts thereof. Furthermore, reaction procedures for the synthesis of the heterobicyclic compound are disclosed.
• Discovery of <i>N</i>-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4<i>H</i>-thieno[2,3-<i>c</i>]pyran-2-yl)-l<i>H</i>-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent
  作者：Steven E. Van der Plas、Hans Kelgtermans、Tom De Munck、Sébastien L. X. Martina、Sébastien Dropsit、Evelyne Quinton、Ann De Blieck、Caroline Joannesse、Linda Tomaskovic、Mia Jans、Thierry Christophe、Ellen van der Aar、Monica Borgonovi、Luc Nelles、Maarten Gees、Pieter Stouten、Jan Van Der Schueren、Oscar Mammoliti、Katja Conrath、Martin Andrews

  DOI：10.1021/acs.jmedchem.7b01288

  日期：2018.2.22

  Cystic fibrosis (CF) is caused by mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR). With the discovery of Ivacaftor and Orkambi, it has been shown that CFTR function can be partially restored by administering one or more small molecules. These molecules aim at either enhancing the amount of CFTR on the cell surface (correctors) or at improving the gating function of the CFTR channel (potentiators). Here we describe the discovery of a novel potentiator GLPG1837, which shows enhanced efficacy on CFTR mutants harboring class III mutations compared to Ivacaftor, the first marketed potentiator. The optimization of potency, efficacy, and pharmacokinetic profile will be described.